Table 2.
Cardiac function classification, treatment strategies, and prognosis in 16 patients with pulsus alternans
| Parameters | NYHA | Therapy | Follow-up (months) | Outcomes |
|---|---|---|---|---|
| Case 1 | III | Calcium channel blockers, β-blocker | 39 | Serial follow-up |
| Case 2 | II | ARBs, Aspirin | 21 | Serial follow-up |
| Case 3 | II | Furosemide, spironolactone, ARBs | 2 | Rehospitalization |
| Case 4 | IV | Furosemide | 44 | Serial follow-up |
| Case 5 | II | Furosemide, antibiotics | 39 | Serial follow-up |
| Case 6 | IV | Furosemide, spironolactone, trimetazidine | 38 | Serial follow-up |
| Case 7 | III | β-blocker, ARBs, furosemide, spironolactone | 32 | Serial follow-up |
| Case 8 | IV | Furosemide, spironolactone, ARBs, trimetazidine | 32 | Serial follow-up |
| Case 9 | IV | Furosemide, ARBs, β-blocker | 2 | Heart transplantation |
| Case 10 | III | Furosemide, spironolactone, ARBs | 31 | Serial follow-up |
| Case 11 | III | Antibiotics, ARBs | 6 | Serial follow-up |
| Case 12 | III | ARBs, β-blocker, spironolactone | 20 | Serial follow-up |
| Case 13 | IV | Antibiotics, furosemide, lyophilized recombinant human brain natriuretic peptide | 1 | Death |
| Case 14 | III | ARBs, β-blocker | 1 | Rehospitalization |
| Case 15 | IV | Spironolactone, torsemide, β-blocker | 7 | Heart transplantation |
| Case 16 | III | spironolactone, furosemide, β-blocker, ARBs | 15 | Serial follow-up |
NYHA New York Heart Association, ARBs Angiotensin II receptor blockers